相关实验视频

Updated: Jul 10, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

转移性细胞癌的现实世界治疗序列和结果

Gu-Shun Lai^1,2, Jian-Ri Li^1,2,3, Shian-Shiang Wang^1,2,4

¹Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

|November 22, 2023

概括

在转移性细胞癌中,一线阿西蒂尼布加布罗利祖马布在现实数据中显示,与氨酸激酶抑制剂或伊皮利穆马布加尼沃卢马布相比,第一线阿西蒂尼布加布的生存率有所改善.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
细胞癌研究细胞癌研究

背景情况:

转移性细胞癌 (mRCC) 的治疗环境已经发生了显著的变化.
现实世界的数据对于理解治疗序列和结果至关重要.

研究的目的:

评估mRCC的现实世界治疗序列和结果.
为了比较一线全身疗法,包括氨酸激酶抑制剂 (TKIs),伊皮利穆马布加尼沃卢马布,布罗利祖马布加阿克西替尼.

主要方法:

来自TriNetX网络的mRCC患者的回顾性分析 (2009年1月 - 2023年5月).
患者接受了一线TKIs,伊皮利穆马布/尼沃卢马布或潘布罗利祖马布/阿克西替尼.
使用Kaplan-Meier方法评估了整体存活率 (OS),治疗时间 (TOT) 和下一次治疗的时间 (TTNT).

主要成果:

与TKIs (2.5和16.6个月) 和ipilimumab/nivolumab (5.4和16.6个月) 相比, pembrolizumab加上axitinib的治疗时间 (8.3个月) 和下一次治疗时间 (22.1个月) 的中位数更长.
布罗利祖马布加上阿克西替尼比TKI (42.2个月;日志排名p = 0.0168) 显示出显著的整体生存益处 (中位数未达到).
伊皮利马布加尼沃马布队列有更多的并发病和远程转移.

结论:

在现实实践中,在mRCC中观察到一线基于免疫瘤学的治疗趋势.
阿克西提尼布加布罗利祖马布比TKI和伊皮利穆马布加尼沃卢马布提供了生存益处.
伊皮利穆马布加尼沃卢马布可能与更高的并发病负担和疾病进展有关.

更多相关视频

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...